Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3269099 | 0.92 | CHRM4 (0.43) | DEGS1MAOAMAOBCHRM4L3MBTL1 | |
| SCHEMBL3265671 | 0.90 | DEGS1 (0.49) | DEGS1L3MBTL1KDM4EMAPTPDE10A | |
| SCHEMBL3266210 | 0.88 | CHRM4 (0.45) | CHRM4CHRM2CHRM1PDE10A | |
| SCHEMBL3269077 | 0.88 | CHRM4 (0.49) | CHRM4L3MBTL1CHRM2CHRM1KDM4E | |
| SCHEMBL3265639 | 0.86 | HRH3 (0.44) | CHRM4MAPT | |
| SCHEMBL3269081 | 0.86 | CHRM4 (0.57) | CHRM4L3MBTL1CHRM2CHRM1KDM4E | |
| SCHEMBL3266214 | 0.85 | CHRM4 (0.43) | CHRM4CHRM2CHRM1MAPT | |
| SCHEMBL3266252 | 0.84 | CHRM4 (0.49) | CHRM4L3MBTL1CHRM2CHRM1 | |
| SCHEMBL3268726 | 0.84 | HRH3 (0.45) | CHRM4PDE10A | |
| SCHEMBL239896 | 0.84 | HRH3 (0.46) | CHRM4PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DEGS1 1658/4885MAOA 2575/4885MAOB 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.